Clinical trials: Pancreatic Adenocarcinoma Resectable
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Pancreatic Adenocarcinoma
A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer
Rational:Pancreatic cancer is a systemic disease at the time of diagnosis, even among patients with apparent localized disease. Surgical resection is the only potentially curative therapy for pancreatic cancer, but in patients…
- Trial name
- nITRo (NCT03528785)
- Testing
- Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Centro Ricerche Cliniche di Verona
Pancreas Cancer, Pancreatic Cancer
A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer
This study is evaluating stereotactic radiosurgery (CyberKnife) plus chemotherapy for the treatment of potentially resectable adenocarcinoma of the pancreas
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma
- Trial name
- NCT02707315
- Testing
- Gemcitabine, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cooper Health System
Pancreatic Cancer
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and…
- Trial name
- NCT00113256
- Testing
- Rubitecan
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine…
- Trial name
- NCT06639724
- Testing
- Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Diego
Pancreatic Cancer
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited.
- Trial name
- NCT03099265
- Testing
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Pancreatic Cancer
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial…
- Trial name
- NCT06141031
- Testing
- TTI-101, Stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
This is a prospective, single-center, randomized, controlled phase Ⅲ study.
- Trial name
- NCT04617821
- Testing
- Nab paclitaxel plus gemcitabine, mFOLFIRINOX
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University